APLAR 2022 Highlights
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Key Presentations<br />
Monday 5th December <strong>2022</strong><br />
1000–<br />
1700<br />
MRI WORKSHOP FOR AXIAL SPA DAY 1<br />
Sponsored by UCB<br />
Tuesday 6th December <strong>2022</strong><br />
0900–<br />
1400<br />
0900–<br />
1400<br />
MRI WORKSHOP FOR AXIAL SPA DAY 2<br />
Sponsored by UCB<br />
GRAPPA SYMPOSIUM<br />
Sponsored by UCB<br />
Chair: Peter Nash<br />
Wednesday 7th December <strong>2022</strong><br />
0800–<br />
0900<br />
0800–<br />
0900<br />
1055–<br />
1200<br />
Hall 5G<br />
PSORIATIC ARTHRITIS – WHAT IS NEW?<br />
Chairpersons: Tin Lok Lai and Howe Hwee Siew<br />
Does psoriasis treatment affect PsA development<br />
Alexis Ogdie<br />
Peripheral spondyloarthritis and psoriatic arthritis: results<br />
of the worldwide, cross-sectional ASAS-PerSpA study<br />
Mitsumasa Kishimoto<br />
ABSTRACT SESSION<br />
Chairpersons: Lie Dai and Samina Ghaznavi<br />
Bimekizumab in Patients with Active Psoriatic Arthritis and<br />
an Inadequate Response to TNF Inhibitors: BE COMPLETE<br />
16-Week Efficacy and Safety<br />
Yoshiya Tanaka<br />
Safety of the JAK inhibitors in comparison with<br />
the TNF inhibitors in RA:real world data from the<br />
HK Biologics Registry<br />
Chi Chiu Mok<br />
Application and simplification of the global pain<br />
assessment scale in patients with rheumatoid arthritis<br />
Biyu Shen<br />
Vascular effect of treat to target in early rheumatoid<br />
arthritis patients – a 5uyear prospective study<br />
Huan Meng<br />
OPENING THE DOOR TOWARDS FREEDOM FROM<br />
PSORIATIC ARTHRITIS<br />
Sponsored by Janssen<br />
Chairperson: Peter Nash<br />
PsA pathophysiology and Interleukin 23 inhibitors<br />
Jonathan Sherlock<br />
Hot topics in PsA management<br />
Peter Nash<br />
The unmet needs of PsA management in daily practice –<br />
it’s more than the joints<br />
Dr Ho So<br />
1055–<br />
1200<br />
S423-4<br />
1315–<br />
1455<br />
1335–<br />
1455<br />
Hall 5G<br />
1455–<br />
1610<br />
1640–<br />
1755<br />
THE ROLE OF A NEW-GENERATION JAK<br />
INHIBITOR IN THE TREATMENT OF RHEUMATOID<br />
ARTHRITIS<br />
Sponsored by GILEAD<br />
Chairperson: Tsutomu Takeuchi<br />
The Role of a New-Generation JAK inhibitor in The<br />
Treatment of Rheumatoid Arthritis.<br />
Mitsumasa Kishimoto<br />
RAPID FIRE POSTER PRESENTATIONS<br />
Association of Baseline Characteristics with Minimal<br />
Disease Activity of Guselkumab Treatment in Biologic-<br />
Experienced PsA Patients: Phase IIIb COSMOS Clinical Trial<br />
Masaru Kato<br />
Bimekizumab Improves Signs and Symptoms of Active<br />
Non-Radiographic Axial Spondyloarthritis: 24-Week Results<br />
from the Phase 3 BE MOBILE 1 Study<br />
Huji Xu<br />
EXPANDING KNOWLEDGE ON TOFACITINIB FOR<br />
THE TREATMENT OF RA<br />
Sponsored by Pfizer<br />
Chairperson: Chi Chiu Mok<br />
Tofacitinib in RA: Learnings and implications from recent<br />
efficacy and safety data<br />
Kunihiro Yamaoka<br />
Recent updates and recommendations for the management<br />
of RA: Implications for clinical practice<br />
Andreas Kerschbaumer<br />
Real-world data for advanced RA treatments: Learnings<br />
from Hong Kong<br />
Chi Chiu Mok<br />
EULAR SYMPOSIUM: RHEUMATOID ARTHRITIS<br />
REMISSION – FROM CLINICAL DEFINITIONS TO<br />
IMAGING ASSESSMENT. WHAT IS NEW?<br />
Chairpersons: Yoshiya Tanaka and Lai Shan Tam<br />
EMERGING CONCEPTS IN SPONDYLOARTHRITIS<br />
Chairpersons: James Wei and Simon Stebbings<br />
The gut and spondyloarthritis: emerging evidence<br />
and controversies<br />
Dirk Elewaut<br />
Uveitis and spondyloarthritis: more than meets the eye<br />
Muhammad Haroon<br />
Treat-to-target in spondyloarthritis – data from the <strong>APLAR</strong><br />
SpA registry<br />
Lai-Shan Tam<br />
1800–<br />
1900<br />
S421<br />
1800–<br />
1900<br />
S423-4<br />
JAK INHIBITION – ARE THE PROMISES FULFILLED?<br />
Sponsored by The Cytokine Signalling Forum<br />
Chair: Lai-Shan Tam<br />
JAK inhibitors in RA – where do they fit in the<br />
treatment paradigm?<br />
Ernest Choy<br />
The therapeutic landscape of PsA treatment<br />
Peter Nash<br />
Latest overview of the management of axSpA<br />
Hideto Kameda<br />
NO PATIENT LEFT BEHIND: A HOLISTIC APPROACH<br />
TO THE TREATMENT OF PATIENTS WITH SPA<br />
Sponsored by UCB<br />
Chair: James Wei<br />
A Holistic Approach to the Treatment of axSpA<br />
Ho Yin Chung<br />
Management of PsA: Refractory Patients and Continuity<br />
of Treatment<br />
Pui-Ying Leong<br />
Elevating Treatment Targets in SpA<br />
James Wei<br />
Thursday 8th December <strong>2022</strong><br />
0900–<br />
1030<br />
1055–<br />
1200<br />
S423-4<br />
1335–<br />
1455<br />
Hall 5G<br />
PLENARY SESSION 2<br />
Chairpersons: Debashish Danda and Ronald Yip<br />
The AxSpA spectrum – using pathogenesis to apply<br />
therapeutic strategies?<br />
Iain McInnes<br />
<strong>2022</strong> updates of RA treatment from Japanese experiences<br />
Tsutomu Takeuchi<br />
RAISING THE BAR FOR PATIENTS WITH SPA:<br />
TREATMENT TARGETS AND A LOOK TO THE FUTURE<br />
Sponsored by UCB<br />
Chair: Huji Xu<br />
Aiming for More Stringent Treatment Targets for Patients<br />
Across the axSpA Spectrum<br />
Huji Xu<br />
Treating to Target in the PsA Clinic<br />
Atul Deodhar<br />
The Evolving Therapeutic Landscape of axSpA and PsA<br />
Huji Xu and Atul Deodhar<br />
BENEFIT: RISK OF JAK INHIBITORS –<br />
WHAT ARE THEIR CLINICAL CONTEXTS?<br />
Sponsored by Abbvie<br />
Chair: Lai-Shan Tam<br />
Clinical context of JAK inhibitors in RA<br />
Kunihiro Yamaoka<br />
1640–<br />
1755<br />
1800–<br />
1900<br />
Hall 5G<br />
2000–<br />
2115<br />
ANKYLOSING SPONDYLITIS –<br />
FROM BENCH TO BEDSIDE<br />
Chairpersons: Jeiro Gu and Sami Salman<br />
Therapies for spondyloarthritis: past, present and future<br />
Iain McInnes<br />
ADVANCES IN THE TREATMENT OF<br />
SPONDYLOARTHRITIS AND RHEUMATOID<br />
ARTHRITIS<br />
Sponsored by Lilly<br />
Chairpersons: Gavin Lee & Carmen Ho<br />
Discussing Spondyloarthritis: Ixekizumab and its relevance<br />
to Clinical Practice<br />
Xenofon Baraliakos<br />
How clinical data and real-world evidence are changing<br />
the treatment of Rheumatoid Arthritis<br />
Yuko Kaneko<br />
HOLISTIC MANAGEMENT OF PSORIATIC<br />
ARTHRITIS – WHERE ARE WE NOW?<br />
Chairpersons: Muhammad Ahmed Saeed and Nazrul Islam<br />
Collaborating with dermatology: practice beyond diagnosing<br />
Kichul Shin<br />
Inflammation and metabolic syndrome: lessons learnt from<br />
psoriatic disease<br />
Muhammad Haroon<br />
Composite measures for PsA outcomes<br />
Katy Leung<br />
Friday 9th December <strong>2022</strong><br />
0800–<br />
0900<br />
0800–<br />
0900<br />
ABSTRACT SESSION<br />
Chairpersons: Shirley Chan and B.G. Dharmanand<br />
Efficacy and safety of bimekizumab in Chinese patients<br />
with active Ankylosing Spondylitis from the Phase 3 study<br />
BE MOBILE 2<br />
Huji Xe<br />
Dysbiosis of the gut microbiota in patients with psoriatic<br />
arthritis is closely related to lymphocyte subsets and<br />
cytokines<br />
Sheng-Xiao Zhang<br />
ABSTRACT SESSION<br />
Chairpersons: Mei Yan Clara Law and Chit Soe<br />
Are we treating to target in spondyloarthritis (SpA)?<br />
a cross sectional analysis from the Asia Pacific League<br />
of Associations for Rheumatology (<strong>APLAR</strong>) SpA registry<br />
Isaaz Tsz Ho Cheng<br />
Male SpA patients with longer disease duration have less<br />
severe disc degeneration – a propensity-score matched<br />
comparison with the population<br />
Tin Yan Samuel Cheung<br />
Clinical context of JAK inhibitors in SpA<br />
Denis Poddubnyy